ProKidney Corp has a consensus price target of $10.38, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from Morgan Stanley, B of A Securities, and BTIG on March 7, 2024, January 2, 2024, and July 25, 2023. With an average price target of $7 between Morgan Stanley, B of A Securities, and BTIG, there's an implied 75.00% upside for ProKidney Corp from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/07/2024 | Buy Now | -25% | Morgan Stanley | Judah Frommer | → $3 | Assumes | → Equal-Weight | Get Alert |
01/02/2024 | Buy Now | -50% | B of A Securities | Jason Gerberry | $8 → $2 | Downgrade | Buy → Neutral | Get Alert |
07/25/2023 | Buy Now | 300% | BTIG | Justin Zelin | → $16 | Initiates | → Buy | Get Alert |
12/21/2022 | Buy Now | 275% | Jefferies | Kelly Shi | → $15 | Initiates | → Buy | Get Alert |
11/10/2022 | Buy Now | 225% | Morgan Stanley | Vikram Purohit | → $13 | Initiates | → Equal-Weight | Get Alert |
10/18/2022 | Buy Now | 350% | UBS | Colin Bristow | → $18 | Initiates | → Buy | Get Alert |
10/14/2022 | Buy Now | 300% | Citigroup | Yigal Nochomovitz | → $16 | Initiates | → Buy | Get Alert |
09/02/2022 | Buy Now | — | Evercore ISI Group | Jonathan Miller | — | Initiates | → Outperform | Get Alert |
The latest price target for ProKidney (NASDAQ: PROK) was reported by Morgan Stanley on March 7, 2024. The analyst firm set a price target for $3.00 expecting PROK to fall to within 12 months (a possible -25.00% downside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for ProKidney (NASDAQ: PROK) was provided by Morgan Stanley, and ProKidney their equal-weight rating.
There is no last upgrade for ProKidney.
The last downgrade for ProKidney Corp happened on January 2, 2024 when B of A Securities changed their price target from $8 to $2 for ProKidney Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProKidney, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProKidney was filed on March 7, 2024 so you should expect the next rating to be made available sometime around March 7, 2025.
While ratings are subjective and will change, the latest ProKidney (PROK) rating was a with a price target of $0.00 to $3.00. The current price ProKidney (PROK) is trading at is $4.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.